HIV Vaccines: New Frontiers in Vaccine Development | Zendy

Ann Duerr | Zendy; Judith N. Wasserheit | Zendy; Lawrence Corey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HIV Vaccines: New Frontiers in Vaccine Development

Author(s) -

Ann Duerr,

Judith N. Wasserheit,

Lawrence Corey

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/505979

Subject(s) - virology , medicine , hiv vaccine , aids vaccines , lentivirus , viral vector , dna vaccination , immunology , recombinant dna , human immunodeficiency virus (hiv) , antibody , vector (molecular biology) , virus , cytotoxic t cell , hiv antigens , vaccine trial , viral disease , immunization , biology , gene , in vitro , biochemistry

A human immunodeficiency virus (HIV) vaccine is the most promising and feasible strategy to prevent the events during acute infection that simultaneously set the course of the epidemic in the community and the course of the disease for the individual. Because safety concerns limit the use of live, attenuated HIV and inactivated HIV, a variety of alternate approaches is being investigated. Traditional antibody-mediated approaches using recombinant HIV envelope proteins have shown no efficacy in 2 phase III trials. Current HIV vaccine trials are focusing primarily on cytotoxic T lymphocyte-mediated products that use viral vectors, either alone or as boosts to DNA plasmids that contain viral genes. The most immunogenic of these products appear to be the recombinant adenovirus vector vaccines, 2 of which are now in advanced clinical development.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research